JP2016512504A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512504A5
JP2016512504A5 JP2016500921A JP2016500921A JP2016512504A5 JP 2016512504 A5 JP2016512504 A5 JP 2016512504A5 JP 2016500921 A JP2016500921 A JP 2016500921A JP 2016500921 A JP2016500921 A JP 2016500921A JP 2016512504 A5 JP2016512504 A5 JP 2016512504A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
substituted
phenyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016500921A
Other languages
English (en)
Japanese (ja)
Other versions
JP6386527B2 (ja
JP2016512504A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/022238 external-priority patent/WO2014143607A1/en
Publication of JP2016512504A publication Critical patent/JP2016512504A/ja
Publication of JP2016512504A5 publication Critical patent/JP2016512504A5/ja
Application granted granted Critical
Publication of JP6386527B2 publication Critical patent/JP6386527B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016500921A 2013-03-11 2014-03-10 カリウムイオンチャネル阻害剤としてのピロロピリダジン Expired - Fee Related JP6386527B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775742P 2013-03-11 2013-03-11
US61/775,742 2013-03-11
PCT/US2014/022238 WO2014143607A1 (en) 2013-03-11 2014-03-10 Pyrrolopyridazines as potassium ion channel inhibitors

Publications (3)

Publication Number Publication Date
JP2016512504A JP2016512504A (ja) 2016-04-28
JP2016512504A5 true JP2016512504A5 (enExample) 2017-04-13
JP6386527B2 JP6386527B2 (ja) 2018-09-05

Family

ID=50382739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016500921A Expired - Fee Related JP6386527B2 (ja) 2013-03-11 2014-03-10 カリウムイオンチャネル阻害剤としてのピロロピリダジン

Country Status (6)

Country Link
US (1) US9458164B2 (enExample)
EP (1) EP2970295B1 (enExample)
JP (1) JP6386527B2 (enExample)
CN (1) CN105008366B (enExample)
ES (1) ES2616026T3 (enExample)
WO (1) WO2014143607A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143606A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
CN105008347A (zh) 2013-03-11 2015-10-28 百时美施贵宝公司 作为钾离子通道抑制剂的异喹啉类化合物
BR112020015444A2 (pt) * 2018-01-30 2020-12-08 Buckman Laboratories International, Inc Método para controlar o crescimento de pelo menos um microrganismo em um produto, método para controlar o crescimento de pelo menos um microrganismo contaminante em um estoque de abastecimento contendo carboidrato fermentável, método para produzir etanol por fermentação com crescimento controlado de microrganismos contaminantes e solução aquosa
EP4651951A1 (en) * 2023-01-19 2025-11-26 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2025008227A1 (en) 2023-07-05 2025-01-09 Basf Se Substituted pyridyl/pyrazinyl dihydropyrrolotriazine compounds for combatting phytopath-ogenic fungi
WO2025008226A1 (en) 2023-07-05 2025-01-09 Basf Se Substituted quinolyl/quinoxalyl dihydropyrrolotriazine compounds for combatting phyto-pathogenic fungi
WO2025077671A1 (zh) * 2023-10-09 2025-04-17 浙江海正药业股份有限公司 多取代芳基类衍生物及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
CA2373990C (en) * 1999-05-21 2007-05-08 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
HUP0303897A2 (hu) * 2000-11-17 2004-03-01 Bristol-Myers Squibb Company Eljárások p38 kinázzal összafüggő esetek kezelésére, kináz inhibitorokként alkalmazható pirrolotriazin vegyületek és ezeket tartalmazó gyógyszerkészítmények
US6900208B2 (en) * 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
BRPI0410097A (pt) * 2003-05-07 2006-05-16 Pharmacia & Upjohn Co Llc compostos de pirrol[1,2-b]piridazina
WO2008029152A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP2134716A1 (en) * 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
MX2010001824A (es) * 2007-08-17 2010-04-21 Icagen Inc Heterociclos como moduladores de canal de potasio.
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
AR077428A1 (es) 2009-07-29 2011-08-24 Sanofi Aventis (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
HRP20161669T1 (hr) 2009-09-03 2017-02-24 Bristol-Myers Squibb Company Kinolini kao inhbitori kalijevih ionskih kanala
EP2623505B1 (en) 2010-09-29 2015-07-29 Kissei Pharmaceutical Co., Ltd. (aza)indolizine derivatives as xanthine oxidase inhibitors
WO2012125893A1 (en) * 2011-03-17 2012-09-20 Bristol-Myers Squibb Company Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
EP2685982B1 (en) * 2011-03-17 2017-07-05 Bristol-Myers Squibb Company Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
US8921368B2 (en) * 2011-03-17 2014-12-30 Bristol-Myers Squibb Company Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
MY169219A (en) * 2012-06-11 2019-03-19 Bristol Myers Squibb Co Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 ? sulfonamide
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2014143606A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
CN105008347A (zh) 2013-03-11 2015-10-28 百时美施贵宝公司 作为钾离子通道抑制剂的异喹啉类化合物
US9242966B2 (en) 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors

Similar Documents

Publication Publication Date Title
JP2016512505A5 (enExample)
JP2016514129A5 (enExample)
JP2016512504A5 (enExample)
JP2016516691A5 (enExample)
JP2019034943A5 (enExample)
JP2016530259A5 (enExample)
JP2012532112A5 (enExample)
JP2019094345A5 (enExample)
JP2015500843A5 (enExample)
JP2015145426A5 (enExample)
JP2019517487A5 (enExample)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2015500223A5 (enExample)
JP2018524390A5 (enExample)
JP2016531126A5 (enExample)
JP2014015465A5 (enExample)
JP2014037426A5 (enExample)
JP2017526727A5 (enExample)
JP2016517417A5 (enExample)
JP2014511892A5 (enExample)
JP2017517538A5 (enExample)
JP2018537535A5 (enExample)
JP2013527847A5 (enExample)
JP2016510326A5 (enExample)
JP2016528273A5 (enExample)